CAIN CHRISTOPHER W. 4
4 · Viridian Therapeutics, Inc.\DE · Filed Jul 2, 2025
Insider Transaction Report
Form 4
CAIN CHRISTOPHER W.
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-07-01+21,000→ 21,000 total(indirect: See Footnote)Exercise: $14.47Exp: 2035-07-01→ Common Stock (21,000 underlying)
Footnotes (2)
- [F1]The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
- [F2]Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.